Neuphoria Therapeutics Inc. (NEUP) — 10-K Filings
All 10-K filings from Neuphoria Therapeutics Inc.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Neuphoria Advances BNC210 to Phase 3 for SAD, PTSD; Nabs $15M Merck Milestone
— Sep 29, 2025 Risk: high
Neuphoria Therapeutics Inc. (NEUP) is a clinical-stage biotechnology company focused on neuropsychiatric disorders. The company is advancing its lead drug candi - 10-K Filing — Sep 30, 2024
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX